ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

In this episode, OncLive On Air^® partnered with Two Onc Docs to bring you insights on the phase 3 ADRIATIC trial (NCT03703297), which investigated durvalumab (Imfinzi) with or without tremelimumab (Imjudo) vs placebo as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not progressed following concurrent chemoradiotherapy. The findings from the durvalumab monotherapy and placebo arms of this trial were presented at the 2024 ASCO Annual Meeting by David R. Spigel, MD, of Sarah Cannon Research Institute in Nashville, Tennessee. In this episode, Drs Armstrong and Tawagi reviewed common risk factors, pathology, presentation, and staging of SCLC; the current standard of care for patients with LS-SCLC; and key findings from ADRIATIC that inspired a standing ovation at ASCO.